Contact Zen Life Supplements

Contact one of our Customer Care Representatives by any of the methods below

Email

Email is the best way to get the fastest response from us. Click the email address below to send us a note.

support@zenlifesupplements.com

 

Returns may be sent to:

Attn: Zen Life Supplements Returns
3 17th Ave South
Nampa, ID 83651
Note: our business headquarters are in Denver. There is no directory listing for us in Idaho.

Online

Your Name (required)

Your Email (required)

Subject:

How Can We Help You?

 

  1. Harvard Health Publications. "What causes depression?". Originally published: June 2009. Accesed: July 2016. 
  2. Rejuvenation Res. 2013 Aug; 16. "Neuropharmacological Review of the Nootropic Herb Bacopa monnieri". Sebastian Aguiar and Thomas Borowski 
  3. Phytomedicine. 2002 Apr;9(3):207-11.  “Antidepressant activity of standardized extract of Bacopa monniera in experimental models of depression in rats.”  Sairam K, Dorababu M, Goel RK, Bhattacharya SK.
  4.  Proc Natl Acad Sci U S A. 2013 Mar 19;110(12):4804-9.  “L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors.”  Nasca C, Xenos D, Barone Y, Caruso A, Scaccianoce S, Matrisciano F, Battaglia G, Mathé AA, Pittaluga A, Lionetto L, Simmaco M, Nicoletti F.
  5. Altern Med Rev. 1999 Jun;4(3):144-61. “A review of nutrients and botanicals in the integrative management of cognitive dysfunction.”  Kidd PM.
  6. Ideggyogy Sz. 2012 Nov 30;65(11-12):387-93.  “Vinpocetin in neurological diseases.”  Szapáry L, Késmárky G, Tóth K, Misnyovszky M, Tóth T, Balogh A, Nagy K, Németh GY, Fehér G.
  7. Neurosci Lett. 2010 Apr 12;473(3):202-7.  “Phosphodiesterase type 1 inhibition improves learning in rats exposed to alcohol during the third trimester equivalent of human gestation.”  Filgueiras CC, Krahe TE, Medina AE.
  8. J Psychoactive Drugs. 2011 Jan-Mar;43(1):1-5.  “Reversing brain damage in former NFL players: implications for traumatic brain injury and substance abuse rehabilitation.”  Amen DG, Wu JC, Taylor D, Willeumier K.
  9. Ideggyogy Sz. 2003 May 20;56(5-6):166-72.  “Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine.”  Hadjiev D.
  10. Neuropharmacology. 2014 Jan;76 Pt B:351-9.  “Reward and aversion in a heterogeneous midbrain dopamine system.”  Lammel S, Lim BK, Malenka RC.
  11. Neuropsychiatr Dis Treat. 2012; 8: 323–328. "5-HTP efficacy and contraindications". Marty Hinz, Alvin Stein, and Thomas Uncini 
  12. MedGenMed. 2004; 6(2): 46. "The Therapeutic Potential of Melatonin: A Review of the Science". Samir Malhotra, MD, Girish Sawhney, MD, and Promila Pandhi, MD 
  13. Eur Rev Med Pharmacol Sci. 2013 Apr;17(8):1082-9.  “Behavioral profile of Hypericum perforatum (St. John's Wort) extract. A comparison with standard antidepressants in animal models of depression.”  Bukhari IA, Dar.
  14. Herbal Medicine: Biomolecular and Clinical Aspects. 2nd edition. Boca Raton (FL): CRC Press; 2011. Chapter 11.  “Medical Attributes of St. John’s Wort (Hypericum perforatum).”  Klemow KM, Bartlow A, Crawford J, Kocher N, Shah J, Ritsick M.  In: Benzie IFF, Wachtel-Galor S, editors.
  15. Neuropsychobiology. 2013;68(4):193-6.  “Hyperhomocysteinemia in bipolar depression: clinical and biochemical correlates.”  Permoda-Osip A, Dorszewska J, Skibinska M, Chlopocka-Wozniak M, Rybakowski JK.
  16. Am J Psychiatry. 2012 Dec 1;169(12):1267-74.  “Folic acid prevents depressive-like behavior and hippocampal antioxidant imbalance induced by restraint stress in mice.”  Budni J, Zomkowski AD, Engel D, Santos DB, dos Santos AA, Moretti M, Valvassori SS, Ornell F, Quevedo J, Farina M, Rodrigues AL.
  17. Phytother Res. 2013 Jul 30.  “Hypericum perforatum: Pharmacokinetic, Mechanism of Action, Tolerability, and Clinical Drug-Drug Interactions.”  Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, Patanè M, Upton R, Pugliese M, Chimirri S, Mammì M, Palleria C, De Sarro G.
  18. Encephale. 2013 Jun 28. pii: S0013-7006(13)00061-4. “Cellular and molecular effects of the antidepressant hyperforin on brain cells: Review of the literature.”  Bouron A, Lorrain E.
  19. Int J Psychiatry Clin Pract. 2013 Nov;17 Suppl 1:1-7.  “Hypericum extract WS ® 5570 for depression--an overview.”  Gastpar M.
  20. J Affect Disord. 2013 Jun;148(2-3):228-34  “Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression.”  Solomon D, Adams J, Graves N.
  21. Planta Med. 2011 Dec;77(18):1970-6.  “Effects of insulin and St. John's Wort treatments on anxiety, locomotory activity, depression, and active learning parameters of streptozotocin-diabetic rats.”  Can OD, Oztürk Y, Ozkay UD.
  22. Can Fam Physician. 2011 Jun;57(6):659-63.  “Complementary and alternative medicine for the treatment of major depressive disorder.”  Nahas R, Sheikh O.
  23. Phytomedicine. 2011 Jun 15;18(8-9):739-42.  “Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial.”  Singer A, Schmidt M, Hauke W, Stade K.
  24. Mol Psychiatry. 2011 Nov;16(11):1088-95  “Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment.”  Molendijk ML, Bus BA, Spinhoven P, Penninx BW, Kenis G, Prickaerts J, Voshaar RC, Elzinga BM.
  25. Eur Neuropsychopharmacol. 2010 Nov;20(11):747-65  “Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression.”  Kasper S, Caraci F, Forti B, Drago F, Aguglia E.
  26. Int Clin Psychopharmacol. 2010 Jul;25(4):204-13.  “Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression.”  Kasper S, Gastpar M, Möller HJ, Müller WE, Volz HP, Dienel A, Kieser M.
  27. Int J Psychiatry Med. 2010;40(1):45-56. “Effects of antidepressive treatment of Saint John's wort extract related to autonomic nervous function in women with irritable bowel syndrome.”  Wan H, Chen Y.
  28. Forsch Komplementmed. 2010 Mar;17(1):7-14. “A hypericum extract in the treatment of depressive symptoms in outpatients: an open study.”  Melzer J, Brignoli R, Keck ME, Saller R.
  29. J Psychiatr Res. 2010 Sep;44(12):760-7.  “St. John's wort extract LI160 for the treatment of depression with atypical features - a double-blind, randomized, and placebo-controlled trial.”  Mannel M, Kuhn U, Schmidt U, Ploch M, Murck H.
  30. Phytomedicine. 2009 Apr;16(4):277-83.  “Long-term effects of St. John's wort (Hypericum perforatum) treatment: a 1-year safety study in mild to moderate depression.”  Brattström A.
  31. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Feb 1;33(1):118-27.  “Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis.”  Rahimi R, Nikfar S, Abdollahi M.
  32. Eur Neuropsychopharmacol. 2008 Nov;18(11):803-13.  “Continuation and long-term maintenance treatment with Hypericum extract WS 5570 after recovery from an acute episode of moderate depression--a double-blind, randomized, placebo controlled long-term trial.”  Kasper S, Volz HP, Möller HJ, Dienel A, Kieser M.
  33. Pharmacopsychiatry. 2006 Mar;39(2):66-75.  “Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study.”  Gastpar M, Singer A, Zeller K.
  34. Eur Neuropsychopharmacol. 2013 Oct;23(10):1219-25  “L-acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine.”  Bersani G, Meco G, Denaro A, Liberati D, Colletti C, Nicolai R, Bersani FS, Koverech A.
  35. Neurochem Int. 2012 Jul;61(1):100-7.  “Chronic acetyl-L-carnitine alters brain energy metabolism and increases noradrenaline and serotonin content in healthy mice.”  Smeland OB, Meisingset TW, Borges K, Sonnewald U.
  36. Curr Opin Gastroenterol. 2012 Mar;28(2):166-76.  “Carnitine derivatives: clinical usefulness.”  Malaguarnera M.
  37. Psychopharmacology (Berl). 2011 Nov;218(2):347-56.  “Antidepressant-like effect of artemin in mice: a mechanism for acetyl-L-carnitine activity on depression.”  Di Cesare Mannelli L, Vivoli E, Salvicchi A, Schiavone N, Koverech A, Messano M, Nicolai R, Benatti P, Bartolini A, Ghelardini C.
  38. Scand J Gastroenterol. 2011 Jun;46(6):750-9.  “Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy.”  Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, Mistretta A, Rampello L, Pennisi G.
  39. Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):953-8.  “Acetyl-l-Carnitine in the treatment of anhedonia, melancholic and negative symptoms in alcohol dependent subjects.”  Martinotti G, Andreoli S, Reina D, Di Nicola M, Ortolani I, Tedeschi D, Fanella F, Pozzi G, Iannoni E, D'Iddio S, Prof LJ.
  40. Eur Neuropsychopharmacol. 2006 May;16(4):281-7.  “A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia.”  Zanardi R, Smeraldi E.
  41. Bipolar Disord. 2002 Feb;4(1):61-6.  “31P-MRS study of acetyl-L-carnitine treatment in geriatric depression: preliminary results.”  Pettegrew JW, Levine J, Gershon S, Stanley JA, Servan-Schreiber D, Panchalingam K, McClure RJ.
  42. Phytomedicine. 2008 Jan;15(1-2):84-91.  “Comparative study of Rhodiola preparations on behavioral despair of rats.”  Panossian A, Nikoyan N, Ohanyan N, Hovhannisyan A, Abrahamyan H, Gabrielyan E, Wikman G.
  43. Neuropsychiatr Dis Treat. 2013;9:639-58.  “Mood disorders and complementary and alternative medicine: a literature review.”  Qureshi NA, Al-Bedah AM.
  44. Phytomedicine. 2012 Sep 15;19(12):1117-24.  “Serotonin involvement in Rhodiola rosea attenuation of nicotine withdrawal signs in rats.”  Mannucci C, Navarra M, Calzavara E, Caputi AP, Calapai G.
  45. Eur Neuropsychopharmacol. 2011 Dec;21(12):841-60.  “Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence.”  Sarris J, Panossian A, Schweitzer I, Stough C, Scholey A.
  46. J Affect Disord. 2011 May;130(3):343-57.  “Second-tier natural antidepressants: review and critique.”  Iovieno N, Dalton ED, Fava M, Mischoulon D.
  47. Phytomedicine. 2009 Sep;16(9):830-8.  “The effects of Rhodiola rosea extract on 5-HT level, cell proliferation and quantity of neurons at cerebral hippocampus of depressive rats.”  Chen QG, Zeng YS, Qu ZQ, Tang JY, Qin YJ, Chung P, Wong R, Hägg U.
  48. J Ethnopharmacol. 2009 Mar 18;122(2):397-401.  “Monoamine oxidase inhibition by Rhodiola rosea L. roots.”  van Diermen D, Marston A, Bravo J, Reist M, Carrupt PA, Hostettmann K.
  49. J Altern Complement Med. 2008 Mar;14(2):175-80.  “A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD).”  Bystritsky A, Kerwin L, Feusner JD.
  50. Nord J Psychiatry. 2007;61(5):343-8.  “Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression.”  Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A.
  51. Transl Psychiatry. 2013 Aug 13;3:e291.  “The effects of congenital brain serotonin deficiency on responses to chronic fluoxetine.”  Sachs BD, Jacobsen JP, Thomas TL, Siesser WB, Roberts WL, Caron MG.
  52. Asian J Psychiatr. 2013 Feb;6(1):29-34.  “Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode.”  Jangid P, Malik P, Singh P, Sharma M, Gulia AK
  53. Pharmacol Ther. 2006 Mar;109(3):325-38.  “Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan.”  Turner EH, Loftis JM, Blackwell AD.
  54. Med Hypotheses. 2005;65(1):138-44.  “5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin.”  Turner EH, Blackwell AD.
  55. Drug Metab Dispos. 2000 Sep;28(9):1038-42.  “Effect of aging on tryptophan hydroxylase in rat brain: implications on serotonin level.”  Hussain AM, Mitra AK.
  56. Altern Med Rev. 1998 Aug;3(4):271-80  “5-Hydroxytryptophan: a clinically-effective serotonin precursor.”  Birdsall TC.
  57. Neuropsychopharmacology. 1997 Jul;17(1):1-11.  “Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder.”  Meltzer H, Bastani B, Jayathilake K, Maes M.
  58. Phytother Res. 2013 Nov 14  “Inhibitory Effect of Bacopasides on Spontaneous Morphine Withdrawal Induced Depression in Mice.”  Rauf K, Subhan F, Abbas M, Ali SM, Ali G, Ashfaq M, Abbas G.
  59. Toxicol Ind Health. 2012 Dec 6.  “Evaluation of standardized Bacopa monniera extract in sodium fluoride-induced behavioural, biochemical, and histopathological alterations in mice.”  Balaji B, Kumar EP, Kumar A.
  60. Curr Med Chem. 2013;20(8):1028-37.  “Preclinical profile of bacopasides from Bacopa monnieri (BM) as an emerging class of therapeutics for management of chronic pains.”  Rauf K, Subhan F, Al-Othman AM, Khan I, Zarrelli A, Shah MR.
  61. Indian J Exp Biol. 2010 Mar;48(3):306-13.  “Comparative evaluation of Bacopa monniera and Panax quniquefolium in experimental anxiety and depressive models in mice.”  Chatterjee M, Verma P, Palit G.
  62. J Altern Complement Med. 2008 Jul;14(6):707-13.  “Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial.”  Calabrese C, Gregory WL, Leo M, Kraemer D, Bone K, Oken B.
  63. Pharmacol Biochem Behav. 2013 Sep;110:224-30.  “The antidepressant-like effect of bacopaside I: possible involvement of the oxidative stress system and the noradrenergic system.”  Liu X, Liu F, Yue R, Li Y, Zhang J, Wang S, Zhang S, Wang R, Shan L, Zhang W.
  64. J Neuroimaging. 1998 Oct;8(4):197-204.  “Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: a PET study.”  Szakáll S, Boros I, Balkay L, Emri M, Fekete I, Kerényi L, Lehel S, Márián T, Molnár T, Varga J, Galuska L, Trón L, Bereczki D, Csiba L, Gulyás B.
  65. J Pharmacol Exp Ther. 2012 Nov;343(2):479-88.  “Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.”  Cai Y, Knight WE, Guo S, Li JD, Knight PA, Yan C.
  66. Int J Dev Neurosci. 2012 Aug;30(5):351-7.  “Early alcohol exposure disrupts visual cortex plasticity in mice.”  Lantz CL, Wang W, Medina AE.
  67. Proc Natl Acad Sci U S A. 2010 May 25;107(21):9795-800.  “Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.”  Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J, Berk BC, Li JD, Yan C.
  68. Eur J Pharmacol. 2009 Oct 12;620(1-3):49-56.  “Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine -- a PDE1 inhibitor.”  Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL.
  69. Orv Hetil. 2007 Jul 22;148(29):1353-8.  “The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies.”  Bagoly E, Fehér G, Szapáry L.
  70. Int Clin Psychopharmacol. 1991 Spring;6(1):31-43.  “Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes.”  Hindmarch I, Fuchs HH, Erzigkeit H.
  71. CNS Neurosci Ther. 2009 Summer;15(2):89-99.  “Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model.”  Nyakas C, Felszeghy K, Szabó R, Keijser JN, Luiten PG, Szombathelyi Z, Tihanyi K.
  72. Ann Anat. 2007;189(1):39-45.  “Effect of vinpocetine on retrograde axoplasmic transport.”  Knyihar-Csillik E, Vecsei L, Mihaly A, Fenyo R, Farkas I, Krisztin-Peva B, Csillik B.
  73. Pharmacopsychiatry. 2013 Sep;46(6):227-8.  “Vitamin B12 level may be related to the efficacy of single ketamine infusion in bipolar depression.”  Permoda-Osip A, Dorszewska J, Bartkowska-Sniatkowska A, Chlopocka-Wozniak M, Rybakowski JK.
  74. Birth Defects Res A Clin Mol Teratol. 2013 Jun;97(6):416-20.  “Red blood cell folate levels in pregnant women with a history of mood disorders: a case series.”  Yaremco E, Inglis A, Innis SM, Hippman C, Carrion P, Lamers Y, Honer WG, Austin J.
  75. Nutrients. 2013 Feb 18;5(2):565-78.  “Socioeconomic status is significantly associated with the dietary intakes of folate and depression scales in Japanese workers (J-HOPE Study).”  Miyaki K, Song Y, Taneichi S, Tsutsumi A, Hashimoto H, Kawakami N, Takahashi M, Shimazu A, Inoue A, Kurioka S, Shimbo T.
  76. Psychiatry Res. 2012 Dec 30;200(2-3):349-53.  “Serum folate and depressive symptoms among Japanese men and women: a cross-sectional and prospective study.”  Nanri A, Hayabuchi H, Ohta M, Sato M, Mishima N, Mizoue T.
  77. J Affect Disord. 2012 May;138(3):473-8.  “Association between folate intake and melancholic depressive symptoms. A Finnish population-based study.”  Seppälä J, Koponen H, Kautiainen H, Eriksson JG, Kampman O, Männistö S, Mäntyselkä P, Oksa H, Ovaskainen Y, Viikki M, Vanhala M.
  78. J Midwifery Womens Health. 2012 Jan-Feb;57(1):43-8.  “Impact of dietary folate intake on depressive symptoms in young women of reproductive age.”  Watanabe H, Ishida S, Konno Y, Matsumoto M, Nomachi S, Masaki K, Okayama H, Nagai Y.
  79. Pharmacol Biochem Behav. 2012 Mar;101(1):148-54.  “Role of potassium channels in the antidepressant-like effect of folic acid in the forced swimming test in mice.”  Budni J, Freitas AE, Binfaré RW, Rodrigues AL.
  80. Psychosom Med. 2010 Nov;72(9):862-73.  “Serum folate, vitamin B-12, and homocysteine and their association with depressive symptoms among U.S. adults.”  Beydoun MA, Shroff MR, Beydoun HA, Zonderman AB.
  81. Am J Clin Nutr. 2010 Aug;92(2):330-5.  “Longitudinal association of vitamin B-6, folate, and vitamin B-12 with depressive symptoms among older adults over time.”  Skarupski KA, Tangney C, Li H, Ouyang B, Evans DA, Morris MC.
  82. Eur J Clin Nutr. 2010 Mar;64(3):289-96.  “Serum folate and homocysteine and depressive symptoms among Japanese men and women.”  Nanri A, Mizoue T, Matsushita Y, Sasaki S, Ohta M, Sato M, Mishima N.
  83. Arch Latinoam Nutr. 2009 Sep;59(3):278-86.  “Micronutrient supplementation may reduce symptoms of depression in Guatemalan women.”  Nguyen PH, Grajeda R, Melgar P, Marcinkevage J, DiGirolamo AM, Flores R, Martorell R.
  84. Expert Rev Neurother. 2009 Sep;9(9):1393-412.  “Homocysteine, folate and vitamin B12 in neuropsychiatric diseases: review and treatment recommendations.”  Stanger O, Fowler B, Piertzik K, Huemer M, Haschke-Becher E, Semmler A, Lorenzl S, Linnebank M.
  85. Ann Gen Psychiatry. 2009 Aug 13;8:18. “Vitamin B12 status in patients of Turkish and Dutch descent with depression: a comparative cross-sectional study.”  Güzelcan Y, van Loon P.
  86. Pol Merkur Lekarski. 2009 Feb;26(152):136-41.  “Does diet affect our mood? The significance of folic acid and homocysteine.”  Karakuła H, Opolska A, Kowal A, Domański M, Płotka A, Perzyński J.
  87. J Hum Nutr Diet. 2009 Apr;22(2):122-33.  “Association between folate, vitamin B(6) and vitamin B(12) intake and depression in the SUN cohort study.”  Sánchez-Villegas A, Doreste J, Schlatter J, Pla J, Bes-Rastrollo M, Martínez-González MA.
  88. Br J Psychiatry. 2008 Apr;192(4):268-74.  “Predictive value of folate, vitamin B12 and homocysteine levels in late-life depression.”  Kim JM, Stewart R, Kim SW, Yang SJ, Shin IS, Yoon JS.
  89. Clin Nutr. 2007 Oct;26(5):545-51.  “Effects of dietary supplements on depressive symptoms in older patients: a randomised double-blind placebo-controlled trial.”  Gariballa S, Forster S.
  90. Clin Biochem. 2007 Jun;40(9-10):604-8.  “Correlation of folate, vitamin B12 and homocysteine plasma levels with depression in an elderly Greek population.”  Dimopoulos N, Piperi C, Salonicioti A, Psarra V, Gazi F, Papadimitriou A, Lea RW, Kalofoutis A.
  91. Curr Drug Targets. 2013 May 1;14(5):514-21.  “Serotonin-kynurenine hypothesis of depression: historical overview and recent developments.”  Oxenkrug G.
  92. Life Sci. 2013 Feb 27;92(3):183-6.  “Association of monoamine-synthesizing genes with the depression tendency and personality in chronic fatigue syndrome patients.”  Fukuda S, Horiguchi M, Yamaguti K, Nakatomi Y, Kuratsune H, Ichinose H, Watanabe Y.
  93. Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:268-76.  “Immune changes and neurotransmitters: Possible interactions in depression?”  Sperner-Unterweger B, Kohl C, Fuchs D.
  94. Brain Behav Immun. 2013 Jul;31:153-60.  “Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations.”  Felger JC, Li L, Marvar PJ, Woolwine BJ, Harrison DG, Raison CL, Miller AH.
  95. Sci Rep. 2012;2:667.  “Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile.”  Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng ZB, Zhu H, Dougherty GG, Yao JK, Chen G, Guitart X, Carlson PJ, Neumeister A, Zarate C, Krishnan RR, Manji HK, Drevets W.
  96. Arch Med Res. 2012 Jul;43(5):375-82.  “Plasma amino acid levels discriminate between control subjects and mildly depressed elderly women.”  Mayoral-Mariles A, Cruz-Revilla C, Vega-Manriquez X, Aguirre-Hernández R, Severiano-Pérez P, Aburto-Arciniega E, Jiménez-Mendoza A, Guevara-Guzmán R.
  97. Gene. 2012 Aug 10;504(2):288-91.  “Depressive symptoms in adolescents with early and continuously treated phenylketonuria: associations with phenylalanine and tyrosine levels.”  Sharman R, Sullivan K, Young RM, McGill J.
  98. Clin Chim Acta. 2012 Jun 14;413(11-12):973-7.  “Simultaneous determination of tyrosine, tryptophan and 5-hydroxytryptamine in serum of MDD patients by high performance liquid chromatography with fluorescence detection.”  Sa M, Ying L, Tang AG, Xiao LD, Ren YP.
  99. J Inherit Metab Dis. 2010 Dec;33 Suppl 3:S417-20.  “Tyrosine monitoring in children with early and continuously treated phenylketonuria: results of an international practice survey.”  Sharman R, Sullivan KA, Young RM, McGill JJ.

ZEN MOOD IS NOT A DRUG and is not intended to diagnose, treat, cure or prevent depression, anxiety, insomnia, or any other disease. ZEN MOOD should not be considered equivalent to or a replacement for FDA-approved medication. Placing an order indicates that you understand and agree to the Terms and Conditions of Sale. For use as a dietary supplement only. This product is not intended to cure, prevent, diagnose, lessen, or mitigate any disease. These statements have not been evaluated by the Food and Drug Administration.

If you're on any prescription drugs or have a medical condition - do not take Zen Mood without first consulting your health care professional.

TESTIMONIALS DISCLAIMER: Testimonials found at zenmood.net and/or from Zen Life Supplements, LLC are unverified results that have been forwarded to us by users of Zen Mood, and may not reflect the typical purchaser's experience, may not apply to the average person and are not intended to represent or guarantee that anyone will achieve the same or similar results. If we have disclosed typical results based on information provided to us by a manufacturer or other reputable third party source, you should presume that the typical results as stated are more reliable than the testimonials and other examples found at zenmood.net and/or from Zen Life Supplements, LLC. However, you should always perform due diligence and not take such results at face value. We are not responsible for any errors or omissions in typical results information supplied to us by manufacturers or other reputable third parties. If a product or service is new, you understand that it may not have been available for purchase long enough to provide an accurate results history. Again, it is possible that even with perfect use of the supplement, you will not achieve the results described in testimonials. They are meant to be a showcase of the best results the product has produced, and should not be taken as the results a typical user will get.

*FTC Legal Disclaimer: Results may vary, and testimonials aren't meant to represent typical results. All testimonials are real, and the users pictured or described improved their mood, felt more emotional stability, optimism, positivity, etc. from taking Zen Life Supplements's Zen Mood. However, these results are meant as a showcase of what the ideal customers experienced and should not be taken as average or typical results.

Individual results will vary and are not guaranteed. This is true of our product, as well as ANY other product on the market. And we want you to be able to make an informed decision when trying Zen Mood.

There is no way to tell if Zen Mood will be effective for you, until you try it. Since it is impossible to promise a desired result for all people, we can't guarantee results, but we will happily guarantee your satisfaction. Please see our Money Back Guarantee.

Please See Our See our full FTC Legal Disclaimer for complete detail.

Do you have questions about Zen Life Supplements or Zen Mood? Are you wondering if the supplement will work for you? Send us an email! You can contact us at support@zenlifesupplements.com. We will go over the ingredients, research, customer feedback and any other supplement you may have tried in the past. Just email support@zenlifesupplements.com, and we'll be happy to help you out.

Models are shown for illustrative purposes. Their use does not imply a personal endorse for any product by them or anyone of their likeness.
Credibility Badges